24 results
8-K
EX-99.1
MIRM
Mirum Pharmaceuticals, Inc.
7 Aug 24
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
4:06pm
and symptoms of CTX include neonatal cholestasis (jaundice or bile flow interruption), chronic diarrhea, the development of bilateral cataracts before
8-K
EX-99.1
ovw jbt9g
29 Sep 21
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
4:42pm
8-K
EX-99.1
4zndo30hyplsf1nrsas
9 Jun 21
Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors
4:17pm
10-K
wghry
12 Mar 20
Annual report
4:16pm
424B4
uo5coom v6d44qrts2
9 Jan 20
Prospectus supplement with pricing info
5:11pm
DRS
2z0ery7wkg4viecpf
27 Dec 19
Draft registration statement
12:00am
424B4
2cr0kfj761dwwt
18 Jul 19
Prospectus supplement with pricing info
4:04pm